<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01480583</url>
  </required_header>
  <id_info>
    <org_study_id>CP1005B016</org_study_id>
    <nct_id>NCT01480583</nct_id>
  </id_info>
  <brief_title>GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases</brief_title>
  <acronym>GRABM-B</acronym>
  <official_title>A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The  purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in
      patients with brain metastases from breast cancer.  For patients with HER2 positive
      metastatic breast cancer, GRN1005 will be assessed in combination with Trastuzumab
      (Herceptin®) as per standard-of-care practice.

      In addition, this study will evaluate the ability of 18F-FLT to determine if the amount of
      change in the uptake in the brain metastases from breast cancer after GRN1005 treatment,
      correlates with intra-cranial response (for patients enrolled at NCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see Brief Summary section.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intra-cranial objective response rate in breast cancer patients with brain metastasis</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability of GRN1005 alone or in combination with Trastuzumab</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-cranial objective response duration</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month intra-cranial progression-free survival</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six month overall survival (OS)</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>GRN1005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRN1005 with trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRN1005</intervention_name>
    <description>550 mg/m2 IV every 3 weeks</description>
    <arm_group_label>GRN1005</arm_group_label>
    <arm_group_label>GRN1005 with trastuzumab</arm_group_label>
    <other_name>ANG1005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice</description>
    <arm_group_label>GRN1005 with trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FLT</intervention_name>
    <description>5 mCi of 18F-FLT IV during Screening and during Cycle 1</description>
    <arm_group_label>GRN1005</arm_group_label>
    <arm_group_label>GRN1005 with trastuzumab</arm_group_label>
    <other_name>18F-fluorothymidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥ 18 years

          2. Histologically or cytologically-documented breast cancer (HER2 status and ER/PgR
             status must be known)

          3. Brain metastasis from breast cancer with or without prior WBRT

          4. At least one radiologically-confirmed and measurable metastatic brain lesion (≥ 1.0
             cm in the longest diameter) by Gd-MRI of the brain &lt; 14 days prior to first dose
             (Metastatic brain lesions previously treated with SRS may not be target or non-target
             lesions)

          5. Patients must be neurologically stable: On stable doses of corticosteroids and
             anticonvulsants (not EIAEDs, including phenytoin, phenobarbitol, carbamazepine,
             fosphenytoin, primidone, oxcarbazepine) for ≥ 5 days prior to obtaining the baseline
             Gd-MRI of the brain and ≥ 5 days prior to first dose

          6. KPS  ≥ 70%

          7. Completed WBRT for intra-cranial lesions ≥ 28 days prior to first dose

        Key Exclusion Criteria:

          1. NCI CTCAE v4.0 Grade ≥ 2 neuropathy

          2. CNS disease requiring immediate neurosurgical intervention (e.g., resection, shunt
             placement, etc.)

          3. Known leptomeningeal disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Castaigne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiochem Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Bates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Frye</last_name>
    <phone>301-402-5958 and 301-451-7868</phone>
    <email>fryer@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betty Lawrence</last_name>
    <phone>514-788-7800</phone>
    <email>blawrence@angiochem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NCI</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Frye</last_name>
      <phone>301-402-5958</phone>
      <email>fryer@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Susan Bates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>November 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GRN1005</keyword>
  <keyword>ANG1005</keyword>
  <keyword>Peptide-Drug Conjugate (PDC)</keyword>
  <keyword>LRP-1</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Blood Brain Barrier</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Breast cancer with brain metastases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
